$14.5m is bugger all actually considering the outgoings and the...

First 19317 Last

Share
Profile

Follow
MurriO

685 Posts.

196

15/02/24

15:56

Post #: 72427196
Share

Originally posted by rusty02: ↑

Not saying anything @Murri0 you are..... $14.5ml isn't bugger all. Lest now you have the information to assess not unfounded blank statements.

As stated in the Financials enough $$ to keep their pathways development on track. No need for hurried CR. Blind Freddy can see that a CR sometime this year must happen. Trials cost $$$ but they have time in negotiations for the right raise whilst our pathways move forward.. I don't see an issue here especially if there is more ongoing support shown in last night's trading.

Allow some tangible news to excite our US counterparts and conditions to raise might become advantageous. Regardless it's not as dire straights as some seem to think. BOD have time to the later part of the year but if a good offer comes along.... why not!!

Agree with you, allowing for new appointees, the rate of increase in salaries last year needs to be contained until solid benchmarks are met Some nice bonuses. As I've always said, you get what you pay for. See what the team can deliver this year.

As for comparison to a doctor's surgery, not sure. A business model that compares a 1/2 hour general consultation to a dedicated 9 month therapy treatment is comparing.

Anyway. Good to see your investment up 12% last night. Settled the nerves.

GL

Expand

$14.5m is bugger all actually considering the outgoings and the cash burn rate

But if you're telling me that's plenty, it's not, why are you saying we need a CR?

Wasn't it just a few months before the Nasdaq redomicile they were saying they were fully funded 'til the end of 25?

IHL Price at posting: 4.1¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply